Management of atopic dermatitis in routine clinical practice

N. Tataurshchikova, O. Letyaeva, A. S. Rusanova
{"title":"Management of atopic dermatitis in routine clinical practice","authors":"N. Tataurshchikova, O. Letyaeva, A. S. Rusanova","doi":"10.32364/2587-6821-2022-6-2-72-78","DOIUrl":null,"url":null,"abstract":"Aim: to assess the efficacy and safety of Admera cream, a cosmetic skin solution for atopic dermatitis (AD). Patients and Methods: this open-label, prospective, observational study enrolled 32 patients aged 3–27 (mean age 14.6±2.4 years) with mild- to-moderate AD. Patients were followed up in the outpatient settings over 1 month. Disease severity was evaluated based on the SCORAD index. Xerosis severity was assessed using a visual analogue scale (VAS). A ≥25% reduction of SCORAD index was considered a significant effect. Admera cream was applied at least once daily. Patients were examined at baseline (screening), on days 1 (visit 1), 14±1 (visit 2), and 28±2 (visit 3). Treatment satisfaction was self-assessed using the 5-point Likert scale. A score of 5 illustrates high treatment satisfaction. Results: the mean SCORAD index was 28.4±7.1 at visit 1 and significantly decreased to 18.2±9.2 after 28 days (p<0.001). The mean VAS score was 5.0±1.0 at baseline, 3.5±1.1 after 14 days, and 2.8±1.4 after 28 days (p<0.001). The mean Likert score was 4.5±0.3 in mild AD and 3.7±0.1 in moderate AD. Among 32 participants, 21 patients (65.6%) rated treatment as \"excellent,” 10 patients (31.2%) as \"good,” and 1 patient (3.1%) as \"satisfactory.” No adverse events were reported. Conclusion: Admera cream is characterized by an excellent safety profile and comfort use. This medication is recommended for long-term treatment of AD. KEYWORDS: atopic dermatitis, xerosis, filaggrin, filagrinol, emollient, care product. FOR CITATION: Tataurshchikova N.S., Letyaeva O.I., Rusanova A.S. Management of atopic dermatitis in routine clinical practice. Russian Medical Inquiry. 2022;6(2):72–78 (in Russ.). DOI: 10.32364/2587-6821-2022-6-2-72-78.","PeriodicalId":21378,"journal":{"name":"Russian Medical Inquiry","volume":"23 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Russian Medical Inquiry","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.32364/2587-6821-2022-6-2-72-78","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 2

Abstract

Aim: to assess the efficacy and safety of Admera cream, a cosmetic skin solution for atopic dermatitis (AD). Patients and Methods: this open-label, prospective, observational study enrolled 32 patients aged 3–27 (mean age 14.6±2.4 years) with mild- to-moderate AD. Patients were followed up in the outpatient settings over 1 month. Disease severity was evaluated based on the SCORAD index. Xerosis severity was assessed using a visual analogue scale (VAS). A ≥25% reduction of SCORAD index was considered a significant effect. Admera cream was applied at least once daily. Patients were examined at baseline (screening), on days 1 (visit 1), 14±1 (visit 2), and 28±2 (visit 3). Treatment satisfaction was self-assessed using the 5-point Likert scale. A score of 5 illustrates high treatment satisfaction. Results: the mean SCORAD index was 28.4±7.1 at visit 1 and significantly decreased to 18.2±9.2 after 28 days (p<0.001). The mean VAS score was 5.0±1.0 at baseline, 3.5±1.1 after 14 days, and 2.8±1.4 after 28 days (p<0.001). The mean Likert score was 4.5±0.3 in mild AD and 3.7±0.1 in moderate AD. Among 32 participants, 21 patients (65.6%) rated treatment as "excellent,” 10 patients (31.2%) as "good,” and 1 patient (3.1%) as "satisfactory.” No adverse events were reported. Conclusion: Admera cream is characterized by an excellent safety profile and comfort use. This medication is recommended for long-term treatment of AD. KEYWORDS: atopic dermatitis, xerosis, filaggrin, filagrinol, emollient, care product. FOR CITATION: Tataurshchikova N.S., Letyaeva O.I., Rusanova A.S. Management of atopic dermatitis in routine clinical practice. Russian Medical Inquiry. 2022;6(2):72–78 (in Russ.). DOI: 10.32364/2587-6821-2022-6-2-72-78.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
特应性皮炎的常规临床处理
目的:评价Admera护肤液治疗特应性皮炎(AD)的疗效和安全性。患者和方法:这项开放标签、前瞻性、观察性研究纳入了32例轻度至中度AD患者,年龄3-27岁(平均年龄14.6±2.4岁)。患者在门诊随访1个月以上。根据SCORAD指数评估疾病严重程度。使用视觉模拟量表(VAS)评估干枯严重程度。SCORAD指数降低≥25%被认为是显著效果。Admera乳霜每天至少使用一次。患者在基线(筛查)、第1天(访视1)、第14±1天(访视2)和第28±2天(访视3)进行检查。采用5点李克特量表自评治疗满意度。5分表示治疗满意度高。结果:患者第一次就诊时的平均SCORAD指数为28.4±7.1,28 d后降至18.2±9.2 (p<0.001)。平均VAS评分基线时为5.0±1.0,14天后为3.5±1.1,28天后为2.8±1.4 (p<0.001)。轻度AD的平均Likert评分为4.5±0.3,中度AD的平均Likert评分为3.7±0.1。在32名参与者中,21名患者(65.6%)认为治疗“优秀”,10名患者(31.2%)认为治疗“良好”,1名患者(3.1%)认为治疗“满意”。无不良事件报告。结论:Admera乳膏具有良好的安全性和使用舒适性。这种药物被推荐用于长期治疗AD。关键词:特应性皮炎,干燥症,聚丝蛋白,聚丝精醇,润肤剂,护理品。引用本文:Tataurshchikova n.s., Letyaeva O.I., Rusanova A.S.特应性皮炎的常规临床实践管理。俄罗斯医学调查。2022;6(2):72-78(俄文)。DOI: 10.32364 / 2587-6821-2022-6-2-72-78。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
0.50
自引率
0.00%
发文量
0
期刊最新文献
Metabolic neuroprotection in patient with chronic heart failure: a case report and study results Poor patient adherence to medication treatments and solutions for overcoming compliance barriers as illustrated by antiplatelet therapy Issues concerning early diagnosis and timely correction of respiratory disorders in amyotrophic lateral sclerosis (literature review) Takayasu's arteritis after coronavirus disease in young woman: case report IBS phenotype associated with obesity and overweight: treatment tactics for patient-centered management
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1